KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Enterprise Value (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Enterprise Value for 9 consecutive years, with -$185.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value rose 14.39% year-over-year to -$185.2 million, compared with a TTM value of -$185.2 million through Dec 2025, up 14.39%, and an annual FY2025 reading of -$185.2 million, up 14.39% over the prior year.
  • Enterprise Value was -$185.2 million for Q4 2025 at Biocryst Pharmaceuticals, up from -$212.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$172.5 million in Q2 2025 and bottomed at -$389.0 million in Q4 2023.
  • Average Enterprise Value over 3 years is -$250.8 million, with a median of -$246.4 million recorded in 2023.
  • Peak annual rise in Enterprise Value hit 44.38% in 2024, while the deepest fall reached 32.93% in 2024.
  • Year by year, Enterprise Value stood at -$389.0 million in 2023, then skyrocketed by 44.38% to -$216.3 million in 2024, then increased by 14.39% to -$185.2 million in 2025.
  • Business Quant data shows Enterprise Value for BCRX at -$185.2 million in Q4 2025, -$212.9 million in Q3 2025, and -$172.5 million in Q2 2025.